Personalis is a technology company.
Personalis has raised $75.0M across 3 funding rounds.
Personalis has raised $75.0M in total across 3 funding rounds.
Personalis has raised $75.0M in total across 3 funding rounds.
Personalis's investors include 1955 Capital, Canvas Ventures, Johnson & Johnson Innovation, Khosla Ventures, Qiming Venture Partners USA, Smash Capital.
# Personalis: Transforming Cancer Care Through Precision Genomics
Personalis is a precision oncology company that develops advanced genomic testing technologies to detect and manage cancer[3][5]. Founded in 2011, the company builds personalized testing solutions designed to transform how cancer is actively managed, combining expertise in advanced testing, cancer genomics, and data science[3][5].
The company serves oncologists, researchers, and patients by providing breakthrough genomic tests that detect ultra-sensitive markers of cancer[3]. Personalis addresses a critical problem in cancer care: the need for earlier detection and more personalized treatment approaches. The company's core mission is to enable precision oncology by developing technologies that increase the potential for tumor detection with the goal of prolonging patient survival[1].
Personalis distinguishes itself through several key capabilities:
Personalis operates within the rapidly expanding precision medicine and oncology genomics sector. The company is riding the wave of declining DNA sequencing costs, increasing computational power, and growing clinical validation of genomic biomarkers for cancer detection and treatment. The timing is particularly significant as healthcare systems increasingly recognize that personalized, data-driven approaches to cancer management can improve outcomes and reduce costs.
By developing technologies that enable earlier detection and more targeted therapies, Personalis influences the broader ecosystem by helping accelerate the shift from one-size-fits-all cancer treatment toward truly personalized oncology.
Personalis is positioned at the intersection of two powerful trends: the democratization of genomic sequencing and the healthcare industry's move toward precision medicine. As cancer detection and treatment become increasingly personalized and data-driven, companies that can reliably identify tumor signatures and support therapy development will become essential infrastructure in oncology.
The company's focus on both detection and therapy development suggests a strategy to embed itself deeply in the cancer care continuum—from diagnosis through treatment selection—which could create significant competitive advantages as the field matures.
Personalis has raised $75.0M across 3 funding rounds. Most recently, it raised $33.0M Series C in January 2015.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2015 | $33.0M Series C | 1955 Capital, Canvas Ventures, Johnson & Johnson Innovation, Khosla Ventures, Qiming Venture Partners USA, Smash Capital | |
| Oct 1, 2013 | $22.0M Series B | 1955 Capital, Canvas Ventures, Johnson & Johnson Innovation, Khosla Ventures, Qiming Venture Partners USA, Smash Capital | |
| Aug 1, 2011 | $20.0M Series A | 1955 Capital, Canvas Ventures, Johnson & Johnson Innovation, Khosla Ventures, Qiming Venture Partners USA, Smash Capital |